文 献 9）Bharwad KD, Shah PA, Shrivastav PS, Singhal P. Development and validation of a rapid and s e n s i t i v e U P L C - M S / M S a s s a y f o r t h e quantification of tofacitinib in human plasma. Biomed Chromatogr 2019; 33: e4458.10）Abdelhameed AS, Attwa MW, Kadi AA. An LC-MS/MS method for rapid and sensitive high-throughput simultaneous determination of various protein kinase inhibitors in human plasma. Biomed Chromatogr 2017; 31: e3793.11）Febvre-James M, Lecureur V, Fardel O. Potent repression of C-reactive protein (CRP) expression by the JAK1/2 inhibitor ruxolitinib in inflammatory human hepatocytes. Inflamm Res 2020; 69: 51-62.12）Febvre-James M, Bruyere A, Le Vee M, Fardel O. The JAK1/2 inhibitor ruxolitinib reverses interleukin-6-mediated suppression of drug-detoxifying proteins in cultured human hepatocytes. Drug Metab Dispos 2018; 46: 131-40.13）Sato H, Naito T, Ishida T, Kawakami J. Relationships between oxycodone pharmacokinetics, central symptoms, and serum interleukin-6 in cachectic cancer patients. Eur J Clin Pharmacol 2016; 72: 1463-70.14）Mimura H, Kobayashi K, Xu L, Hashimoto M, Ejiri Y, Hosoda M, et al. Effects of cytokines on CYP3A4 expression and reversal of the effects by anti-cytokine agents in the three-dimensionally cultured human hepatoma cell line FLC-4. Drug Metab Pharmacokinet 2015; 30: 105-10.15）Ito T, Suno M, Shintani M, Iwata A, Fujii T, Matsubara K. Simultaneous quantification of filgotinib and its active metabolite in human plasma using liquid chromatography-tandem mass spectrometry: Validation and clinical application. Biomed Chromatogr 2025; 39: e70030. 1）Dutt K, Vasudevan A. Therapeutic drug monitoring for biologic and small-molecule therapies for Inflammatory bowel disease. Medicina (Kaunas) 2024; 60: 250. 2）Restellini S, Afif W. Update on TDM (therapeutic drug monitoring) with ustekinumab, vedolizumab and tofacitinib in inflammatory bowel disease. J Clin Med 2021; 10: 1242. 3）Dowty ME, Lin J, Ryder TF, Wang W, Walker GS, Vaz A, et al. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans. Drug Metab Dispos 2014; 42: 759-73. 4）Liu P, Wu S, Dong Z. Identification of the metabolites of tofacitinib in liver microsomes by liquid chromatography combined with high resolution mass spectrometry. Biomed Chromatogr 2021; 35: e5081. 5）Slaviero KA, Clarke SJ, Rivory LP. Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol 2003; 4: 224-32. 6）Enokiya T, Nishikawa K, Hamada Y, Ikemura K, Sugimura Y, Okuda M. Temporary decrease in tacrolimus clearance in cytochrome P450 3A5 non-expressors early after living donor kidney transplantation: Effect of interleukin 6-induced suppression of the cytochrome P450 3A gene. Basic Clin Pharmacol Toxicol 2021; 128: 525-33. 7）Mukherjee A, Hazra A, Smith MK, Martin SW, Mould DR, Su C, et al. Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial. Br J Clin Pharmacol 2018; 84: 1136-45. 8）Sharma K, Giri K, Dhiman V, Dixit A, Zainuddin M, Mullangi R. A validated LC-MS/MS assay for simultaneous quantification of methotrexate and tofacitinib in rat plasma: application to a pharmacokinetic study. Biomed Chromatogr 2015; 29: 722-32.炎症マーカーとPK/PD/PGxの統合解析に基づくトファシチニブの個別化治療法の構築225
元のページ ../index.html#243